modelNevirapine
Extends from Pharmacolibrary.Drugs.ATC.J.J05AG01.
Information
| name: | Nevirapine | |
| ATC code: | J05AG01 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 1.12 | L |
| clearance: | 3.49 | L/h |
| other parameters in model implementation | ||
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of human immunodeficiency virus (HIV)-1 infection. It is typically used in combination with other antiretroviral agents. Nevirapine is approved for use in adults and children and is available in oral tablet and suspension formulations.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers; oral administration of 200 mg nevirapine twice daily.
References
Elsherbiny, D, et al., & Simonsson, US (2009). Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. European journal of clinical pharmacology 65(1) 71–80. DOI:10.1007/s00228-008-0481-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/18751690
Moltó, J, et al., & Clotet, B (2008). Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. The Journal of antimicrobial chemotherapy 62(4) 784–792. DOI:10.1093/jac/dkn268 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18593723
Ibarra, M, et al., & Fagiolino, P (2014). Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose. Journal of pharmacokinetics and pharmacodynamics 41(4) 363–373. DOI:10.1007/s10928-014-9371-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25064169
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)